Timco
co 时间:2021-03-03 阅读:()
CO-1EversenseContinuousGlucoseMonitoring(CGM)SystemMarch29,2018Senseonics,Inc.
ClinicalChemistryandClinicalToxicologyDevicePanelCO-2IntroductionMukulJain,PhDChiefOperatingOfficerSenseonics,Inc.
CO-3EversenseContinuousGlucoseMonitoring(CGM)System90-dayImplantableSensorsubcutaneousRemovableTransmitterwornoverskinMobileApplicationhandhelddeviceCO-4Forcontinuallymeasuringglucoselevelsinadults(age≥18)withdiabetesforoperatinglifeofsensorSystemprovides:Real-timeglucosereadingsGlucosetrendinformationAlertsfordetectionandpredictionofepisodesoflowbloodglucose(hypoglycemia)andhighbloodglucose(hyperglycemia)Adjunctivedevicetocomplement,notreplace,informationobtainedfromstandardhomebloodglucosemonitoringdevicesProposedIndicationforUseCO-5InsertedintoupperarmLastsupto90daysMeasuresglucoseevery5minSiliconecollarcontaining1.
75mgdexamethasoneacetate(DXA)ReduceinflammationaroundsensorSystemComponents:SensorCO-6SensorTechnologyBasedonFluorescenceCO-7SystemComponents:TransmitterCalculatesglucosevaluesandtrendsWornexternallyoverinsertedsensorSecuredwithadhesivepatchVibratesforalertsandnotificationsRechargeableCO-8SystemComponents:MobileMedicalApplicationDisplaysglucoseinformationfromtransmitterValuesandtrendsAlertsandnotificationsRunsonsmartphoneRemindsusertocalibrate(2x/day)OptiontouploaddatatoSenseonics'DataManagementSystemCO-9ThresholdIdentifyglucoselevelsbeloworabovepre-setvaluesPredictiveSignalwhenalertlevelisexpectedtobecrossedinimmediatefuture(e.
g.
10minutesprior)RateofchangeIdentifyrisingorfallingglucoseexceedingpre-setrateofchangeMultipleAlertTypestoEnsureSafetyCO-10Vibratory,Visual,andAudioAlertsTransmittervibrateswhethermobileappisactiveorinvicinityUniquevibrationpatternsAudiblealertANDvisualmessageonhandhelddeviceCO-11SensorInsertedinUpperArmDuringSimple,Office-BasedProcedureSensorinserted/removedbyHCPBrief,office-basedprocedureCustominsertiontoolsProcedure:SkinanesthetizedanddisinfectedSmallincisioninupperarmBluntdissectorcreatessubcutaneouspocketSensortransferredtopocketSimilarremovalprocedureCO-12CEMarkreceivedMay2016Availablein14countries1686patientscommercially2386insertionsUpto7sequentialsensorsPMAsubmittedtoFDAinOctober2016EversenseSystemRegulatoryStatusAsofFebruary2,2018CO-13ClinicalProgram:2224PatientsFeasibilityStudiesN=332PRECISE(EU)Nov2015N=81PRECISEII(US)Jul2016N=90EuropeanPatientRegistryOngoingN=1686PRECISION(US)Feb2018N=35=OngoingstudyCO-14DesignchangessincePRECISEIITransmitterGlucosealgorithmSensorendcapBluntdissectortoolStudyresultsestablishEversenseissafeandeffectiveChangesareincrementalinnatureContinuousimprovementindesignFDADiscussionTopics:DesignChangesCO-15DesignChanges:TransmitterMoreergonomicdesignThinnerLighterLessobtrusiveWater-resistantPassedverificationandvalidationtestingExtensiveEUcommercialexperienceGeneration1PRECISEII+PRECISIONGeneration2PRECISIONCO-16GlucosealgorithmupdatedtoimproveperformanceinEarlysensorwearHypoglycemicrangeRawsensordataindependentofalgorithmintransmitterAlgorithmdevelopedwithdatafromEUpivotalstudy(PRECISE)PosthocprocessingofUSdatacollectedwithSW602EversenseperformanceaccurateandreliablewithStudySWandSW602DesignChanges:GlucoseAlgorithmSMBGCalibrationsValuesFluorescenceMeasurementsGlucoseDeterminationAlgorithmCGMValuesCO-17Amountofdatarelativetosensorlife(90days)AccuracyinearlywearperiodFDADiscussionTopics:SensorAccuracyCO-18Demonstratedaccuracy8.
5%meanabsoluterelativedifference(MARD)87%ofreadingswithin15mg/dLor15%ofreferenceExcursionsconsistentlydetected96%ofhypoglycemicexcursions*98%ofhyperglycemicexcursions*Durationofuse91%ofsensorsfunctionedfor90daysPRECISEII:EversenseSystemisHighlyAccurate*Includes70mg/dLand180mg/dLthresholdsand10-minutepredictivealertsCO-19Nodevice-relatedSAEs1procedure-relatedSAEthrough90dayspost-insertionNounanticipatedAEsLowrateofinfectionsandadhesivepatchskinreactionsAEsconsistentwithotherCGMsandsubcutaneousimplantsEversenseSystemisSafeCO-20RiskanalysisRisksareconsistent,predictable,canbemitigatedSingleinsertioncharacterizesimpact,90-dayuse,removal,andhealingClinicalstudyresultsDeviceandinsertion/removalprocedurearesafeNominal/completehealingfollowingsensorremovalPost-marketingstudiesofrepeatuseEURegistry(1686patients,upto7sequentialsensors)RepeatsensornotassociatedwithincreasedAEsRepeatSensorUseisSafeCO-21AgendaUnmetNeedJeremyH.
Pettus,MDUniversityofCaliforniaatSanDiegoStudyDesignTimGoodnow,PhDSenseonics,Inc.
EffectivenessSafetyLynneKelley,MD,FACSSenseonics,Inc.
Post-approval/TrainingClinicalPerspectiveStevenJ.
Russell,MD,PhDHarvardMedicalSchoolCO-22AdditionalExpertsClinicalPharmacologyNicholasFleischer,RPhPhDVicePresidentClinicalPharmacologyandBiopharmaceuticsTheWeinbergGroupStatisticsRichardHolcomb,PhDConsultantStudyConductKatherineTweden,PhDSenseonics,Inc.
DermatologyHowardI.
Maibach,MDDermatologistProfessorofDermatologyUniversityofCalifornia,SanFranciscoPathologyRenuVirmani,MDFACCPresidentCVPathInstituteCO-23UnmetNeedJeremyH.
Pettus,MDAssistantProfessorofMedicineEndocrinology,DiabetesandMetabolismUniversityofCalifornia,SanDiego(UCSD)CO-24CGMbenefitsImprovedoverallglucosecontrollowerHbA1clevelsIncreasedtimespentwithinnormalglucoserangeImprovedqualityoflifeCGMusesupportedbysocietyguidelines*GreatlyunderutilizedCGMOverviewPolonskyetal.
(2017)*AmericanDiabetesAssociation,EndocrineSociety,andAmericanAssociationofClinicalEndocrinologistsCO-25TARGETRANGE010020030040004812162024IntermittentMonitoringwithHomeBloodGlucoseMeterLeadstoUnnoticedHighsandLowsGlucose(mg/dL)TimeFingersticksCGM4:00AM8:00AM12:00PM4:00PM8:00PM12:00AMCO-26-0.
6-0.
5-0.
4-0.
3-0.
2-0.
100.
10.
2CO-270%20%40%60%80%100%NoCGMCGMCGMProtectsAgainstSevereHypoglycemiaPatientswithSevereHypo-glycemiaperYearA1c:7.
21A1c:7.
121.
DCCTResearchGroup(1993);2.
JDRFCGMStudyGroup(2008)1event/19months1event/60monthsCO-28CGMSystemsAreUnderutilized:76%ofPatientsDoNotUseCGMType1Diabetes(T1D)Exchangeregistry7%24%0%20%40%60%80%100%2010-20122015-2017PatientsUsingCGM(%)YearsCO-2927%ofPatientsDiscontinueCGMUseWithin1YearType1Diabetes(T1D)ExchangeRegistry(2016)ReasonN=262CGMnotworkingproperly/accurateenough71%Problemswithadhesive/insertion61%Tooexpensive/notcoveredbyinsurance58%Uncomfortabletowear41%Usingpump/don'twanttwositesonbody33%CGMtoobig28%CO-30LongersensorlifeLessfrequentsensorinsertionsCurrentsystemsrequire25–50replacements/yearEasytowearandeasilyremovedForphysicalactivitiesordiscretionAdvancementsNeededinCGMSystemsCO-31ProvenclinicalbenefitManypatientshavenotadoptedCGMtechnologyorquicklyabandonitPatientsmissingopportunitytoimprovediabetesstatusandqualityoflifeNeedmoreCGMoptionstoincreasepatientaccessNaturalEvolutionofSensorTechnology:Longer-Lasting,LessIntrusiveCO-32StudyDesignandEffectivenessTimGoodnow,PhDChiefExecutiveOfficerSenseonics,Inc.
CO-33EversenseClinicalProgramStudyDurationPatientsSitesRolePRECISEII90days908USPivotalPRECISION90days353USSupportivePRECISE180days817EUSupportiveEuropeanPatientRegistry(ongoing)2years1686350EUPost-marketFeasibilityStudiesVaried33210PilotTotal2224CO-34Non-randomized,single-arm,multi-centerstudyN=90patientsn=75onesensorinsertedn=15twosensorsinserted(oneineacharm)Sensorscalibrated2x/dayusinghomeglucosemeterGlucosereadingsandhigh/lowalertswereblindedduringstudyPRECISEII:PivotalStudyDesignCO-35PRECISEII:PivotalStudyScheduleClinicVisit1234567Day-3001306090100Screening/Follow-upAccuracy(in-clinic)Challenges**Meal,exercise,compressionchallengesInsertionAt-homewearfor90daysRemovalCO-36Meanabsoluterelativedifference(MARD)ComparessensorreadingwithreferenceglucoseSmallerMARD=higheraccuracyPercentofsensorvalueswithin15mg/dLor15%ofreferencePRECISEII:PrimaryEndpointBasedonMARDCO-37Sensoraccuracyacross90daysofuseAgreementofsensorreadingswithinaccuracylimitsHighandlowglucosealertperformanceImpactofcompressionPairedprecisionKaplan-MeieranalysisofsensorlifeMethodcomparison,biasanalysis,Clarke&ConsensusErrorAnalysisPRECISEII:AdditionalEffectivenessCharacterizationCO-38Adultsdiagnosedwithdiabetesmellitusforatleast1yearNoseverehypoglycemiawithinlast6monthsNodiabeticketoacidosisrequiringhospitalizationwithin6monthsPRECISEII:KeyEnrollmentCriteriaCO-39PRECISEIIDemographics:RepresentativeStudySampleParameterN=90SexMale60%AgeMean45yearsRaceCaucasian86%BlackorAfricanAmerican8%Asian3%Other3%BodyMassIndexMean29kg/m2GlycosylatedHemoglobin(HbA1c)Mean7.
6%TimesincediabetesdiagnosisMean20yearsDiabetestypeType168%Type232%TypeofinsulintherapyContinuousinsulininfusionpump48%Multipledailyinjections27%None(Type2,notoninsulin)22%Other(long-actinginsulinonly)3%CO-40PRECISEII:DispositionConsentedN=114CompletedSensorInsertionN=90CompletedDay1VisitN=90CompletedDay30VisitN=89CompletedDay60VisitN=86CompletedDay90VisitN=82Screenfailures(n=17)Withdrawnpriortoinsertion(n=7)Losttofollowup(n=1)Withdrawnconsent(n=2)Sensorreplacementalert(n=4)Sensorreplacementalert(n=1)CO-41PRECISEII:PrimaryEffectivenessEndpointMetUsingStudySoftwareSoftwareVersionUniquePatientsNPairedValuesNMeanAbsoluteRelativeDifference(95%CI)p-valueStudySW9015,7048.
8%(8.
3%,9.
4%)cosereadingbetweenprimarysensorandreferencevaluesCO-42PRECISEII:PrimaryEffectivenessEndpointMetUsingSW602BasedonallevaluabledatafromallpatientswithatleastonepairedglucosereadingbetweenprimarysensorandreferencevaluesSoftwareVersionUniquePatientsNPairedValuesNMeanAbsoluteRelativeDifference(95%CI)p-valueSW6029015,7538.
5%(8.
0%,9.
1%)CO-43PRECISEII:SensorAccuratethrough90DaysofUseStudyTimePointUniquePatientsNPairedValuesN%ofCGMReadingswithin15/15%ofReference(95%CI)Overall9015,75387%(84.
7%,88.
6%)Day190170877%(72.
8%,80.
4%)Day3088508191%(88.
3%,92.
6%)Day6085472587%(83.
4%,90.
4%)Day9077423985%(81.
8%,88.
4%)020406080100SW602CO-44EversenseClinicalProgramStudyDurationPatientsSitesRolePRECISEII90days908USPivotalPRECISION90days353USSupportivePRECISE180days817EUSupportiveEuropeanPatientRegistry(ongoing)2years1686350EUPost-marketFeasibilityStudiesVaried33210PilotTotal2224CO-45PRECISIONStudyDesignClinicVisit123456789Day-3001714306090100Screening/Follow-upAccuracy(in-clinic)Challenges**Mealchallenges;OvernightchallengeswereperformedonDays7and14InsertionAt-homewearfor90daysRemovalCO-463USsites35patientswithsensorsinserted27patientshad2sensorsinsertedUnblindedsensorglucosevaluesandactivehigh/lowalertsPRECISIONDifferencesfromPRECISEIICO-47PRECISION:SensorAccurateover90DaysofUseStudyTimePointUniquePatientsNPairedValuesN%ofCGMReadingswithin15/15%ofReference(95%CI)Overall3515,17085%(82.
9%,87.
5%)Day135266579%(74.
5%,83.
1%)Day735292686%(81.
5%,89.
7%)Day1435299788%(84.
7%,90.
7%)Day3035228488%(81.
3%,92.
6%)Day6035213387%(79.
7%,91.
8%)Day9035216584%(78.
4%,88.
2%)020406080100SW602CO-48AccuracyComparisonwithApprovedCGMsthroughSensorLifeDataSourcePercentofSystemReadingsWithin15/15%ofReferenceDeviceDay1Day3-4Day7Day10Day14Day30Day60Day90Eversense(SW602)PRECISEII77%91%87%85%PRECISION79%--86%--88%88%87%84%DexcomG5*--77%89%90%MedtronicGuardian(3)*--68%87%82%FreeStyleLibre*--76%82%85%85%*SummaryofSafetyandEffectivenessData(SSED)-MedicalDeviceDatabases-http://www.
fda.
govResultsbasedoncalibrationevery12hoursCO-49AlertSettingPRECISEIIDetectionRateFalseAlertRateLowGlucoseAlertat70mg/dL*96%16%HighGlucoseAlertat180mg/dL*98%7%AccurateDetectionofGlucoseExcursionsPRECISIONDetectionRateFalseAlertRate95%8%99%7%SW602*Includesthresholdand10-minutepredictivealertsCO-50PRECISEII:KMsurvivalprobabilityof91%atDay90PRECISION:Allsensorsfunctioned90daysPRECISEIIandPRECISION:EversenseSensorLongevity0.
00.
20.
40.
60.
81.
00306090SensorSurvivalProbabilityTimesinceImplant(days)0.
00.
20.
40.
60.
81.
00306090PRECISIONPRECISEIICO-51PRECISEIIandPRECISION:SystemAdherencePRECISEIIPRECISIONMedianweartime23.
4hours23.
4hours%transmittersworn>20hours/day87%91%CO-52PRECISEII:87%ofsensorreadingswith15/15%ofreferencePRECISION:85%ofsensorreadingswith15/15%ofreferenceAccurateateachmeasuredtimepointNodegradationofsensorperformance91%ofsensorsfunctionthrough90days"SensorReplacement"alertappropriatelyproducedOver95%detectionratesforglycemicexcursionsHigh(180mg/dL)andlow(70mg/dL)glucoseEffectivenessSummary:EversenseisAccuratefor90DaysCO-53ClinicalSafetyLynneKelley,MD,FACSChiefMedicalOfficerSenseonics,Inc.
CO-54EversensesystemhasacceptablesafetyprofileSimilartoothermarketedCGMsystemsProceduralrisksofimplantablesensormitigatedDevicedesign,training,andcontinuedimprovementsbasedonpost-marketsurveillanceEversensereducessomeknownrisksassociatedwithotherCGMsystemsOverviewofSafetyProfileCO-55EversenseClinicalProgramStudyDurationPatientsSitesRolePRECISEII90days908USPivotalPRECISION90days353USSupportivePRECISE180days817EUSupportiveEuropeanPatientRegistry(ongoing)2years1686350EUPost-marketFeasibilityStudiesVaried33210PilotTotal2224CO-56PRECISEIIandPRECISION:DeviceExposurePRECISEIIPRECISIONSensorsinsertedandremoved106sensors(90patients)62sensors(35patients)Proceduresperformed212procedures124proceduresSensoruse(meanduration)92.
2days91daysSensorexposure9,773days6,148daysCO-57Incidenceofdevice-relatedorinsertion/removalprocedure-relatedseriousadverseevents(SAEs)atanypointduringsensorusePRECISEIIandPRECISION:PrimarySafetyEndpointCO-58Non-seriousrelatedadverseeventsAEsofspecialintereste.
g.
infection,adhesivereactionsDexamethasoneexposureovertimePRECISEIIandPRECISION:AdditionalSafetyAnalysesCO-59PRECISEIINodevice-relatedSAEsOneprocedure-relatedSAEreportedSensorremovalsensorunsuccessful(withandwithoutultrasound)SensorsuccessfullyremovedbysurgeonundergeneralanesthesiaPRECISIONNodevice-orprocedure-relatedSAEs3unrelatedSAEsGastroenteritis,hypoglycemicepisode,cellulitisofleftfootPRECISEIIandPRECISION:SeriousAdverseEvents(SAEs)CO-60AdverseEventPRECISEIIPRECISIONEventsPatientsN=90EventsPatientsN=35AllEvents14785Pain/discomfort4222Bruising22----Erythema22----Devicefragmentnotrecovered22----Syncope11----Tingling11----Delayedreportofpain11----Secondaryproceduretoremovesensor1121Dermatitisatpatchlocation----21Skinhyperpigmentation----21PRECISEIIandPRECISION:Device-orInsertion/Removal-RelatedAEsCO-61Allremovedsensorsreturnedtosponsorforinspection2devicesdidnothavecapuponreturnCorrectiveandpreventativeactionplanimplementedImplementingenhancedqualityprocedures(capadhesion)Capmaterial:PMMAhighlybiocompatible,permanentimplantOrthopedic,dental,andophthalmologicCapsize:3.
2mmx0.
8mmPRECISEII:TwoEventsRelatedtoDeviceFragmentCO-62NoinfectionsAllrelatedAEsconsideredexpectedandcommonforsubcutaneousimplantAllrelatedAEsresolvedfullyPRECISEIIandPRECISION:AdditionalSafetyOutcomesCO-63Contains1.
75mgdexamethasoneacetate(DXA)Water-insolublecorticosteroidReduceslocalinflammatoryresponseExtendssensorlifeControlledandslowDXAreleaseconeCollarCO-64BloodassayedforDXAto50pg/mLlevelNodetectableplasmalevelsofDXAobservedNosystemiceffectsDXAcollarsexaminedafterremovalMinimalDXAexposureconfirmed3μg/day2eventsoftransienthyperpigmentationResolveduponsensorremovalImpactofDexamethasoneExposureCO-65EversenseClinicalProgramStudyDurationPatientsSitesRolePRECISEII90days908USPivotalPRECISION90days353USSupportivePRECISE180days817EUSupportiveEuropeanPatientRegistry(ongoing)2years1686350EUPost-marketFeasibilityStudiesVaried33210PilotTotal2224CO-66Threemulti-centerstudiesPRECISEII,PRECISION,andPRECISE206subjects335sensors670insertion/removalprocedures22,529patient-daysofsensorwearIntegratedDeviceExposureCO-67IntegratedSummaryofRelatedAdverseEventsAdverseEventEventsPatientsN=206AllEvents4126(13%)Pain/discomfort108(4%)Redness/erythema66(3%)Secondaryproceduretoremovesensor43(1%)Infection33(1%)Bruising/hematoma33(1%)Devicefragmentnotrecovered22(1%)Dermatitisatpatchlocation32(1%)Skinhyperpigmentation21(cope,hypertension,andnauseaCO-68Aggregateinfectionrate1%ImprovedincisioncareinstructionsPRECISE:leavebandagefor24hoursPRECISEII:leavebandagefor48hoursInfectionrateobservedisbelowliteraturereportsforsimilarimplantsandminorprocedures:2–4%*LowRateofInfectionsObservedinStudies*Buprenorphine,BraeburnPharmaceuticals,Inc.
*http://www.
worldwidewounds.
com/2005/september/Gottrup/Surgical-Site-Infections-Overview.
htmlCO-69EversenseClinicalProgramStudyDurationPatientsSitesRolePRECISEII90days908USPivotalPRECISION90days353USSupportivePRECISE180days817EUSupportiveEuropeanPatientRegistry(ongoing)2years1686350EUPost-marketFeasibilityStudiesVaried33210PilotTotal2224CO-70AllpatientsinsertedcommerciallyenrolledinregistryEnrollmentcompletedwhen100patientsreach4insertionsAllpatientsenrolledtobefollowedthrough8insertionsandremovalsEuropeanPatientRegistryCO-71LowRateofAEswithRepeatInsertionsEvents,n(%)PostInsertion#1N=16862N=4433N=1434N=585N=396N=147N=3SAEs0000000Device-,procedure-relatedAEsInfection(atsensorsite)8(0.
5%)4(1%)2(1%Secondaryproceduretoremovesensor72Adhesivepatchsiteirritation5-2----Prolongedwoundhealing3Redness/reactiontodressing3Sensorbrokeduringremoval3Skinatrophyoversensorw/skindiscoloration21Skinatrophyoversensor1Skindiscoloration12Sensorsitepain/discomfort1Bruising11-1---Patientfaintedduringprocedure1Hematoma---1---CO-72ProposedPost-ApprovalStudyCO-73Serialsensorinsertionsandremovalsfor2years175patientsinupto20clinicalsitesPrimarysafetyendpointRateofdevice-relatedandinsertion/removalprocedure-relatedSAEsthrough12months≤7%PrimaryeffectivenessendpointTimeinrange(between70mg/dLand180mg/dL),12monthsvs.
firstmonthProposedU.
S.
PostApprovalStudyDesignCO-74AllrelatedAEsthrough2yearsPlasmadexamethasonelevelsevery6monthsEffectivenessoftrainingprogramSuccessrateofinsertions/removalsDiabetesdistressscaleandCGMsatisfactionscaleBaselineandannuallyProposedU.
S.
PostApprovalStudy:OtherOutcomeMeasuresCO-75DesignChangesSensorendcapBluntdissectortoolCO-76SensorEndCapImprovementOriginalDesignNewDesignEndcapredesignedtobeflushwithendofsensorDesignverificationCompressiveforcesTorqueMaintainsfunctionalcompatibilitywithinsertiontoolCO-77BluntDissectorDesignImprovementSamefunctionConsistentplacementfacilitatesremovalProperentryanglePocketdepth/lengthParalleltoskinValidatedwithHumanFactorstestingNewBluntDissectorOriginalBluntDissectorNewguidesCO-78TrainingforCliniciansCO-79MandatorycomprehensivetrainingCertificationprocessledbySenseonicsapprovedtrainersDidacticsessionPracticeswithsimulatedskinInitialinsertionsandremovalsareobservedTrainingProgramOverviewTrainingresources:CGMSensorInsertionandRemovalInstructionsInsertionvideosRemovalvideosSimulationstationProcedureposterTake-homeinstructionsCO-80TrainingChecklistforCertificationPre-WorkbeforeSimulationTrainingInsertionSimulationTrainingPre-WorkbeforeRemovalReviewRemovalSimulationTrainingLearningcurve:~2to3procedures3patientsscheduledinsamedaytofamiliarizewithprocedureCO-81Hands-OnPracticeSessionwithSimulatedSkin,SterileField,andRequiredSuppliesCO-82ExamplesofTrainingMaterialsCO-83461clinicianstrainedoninsertions94%certifiedtodoinsertionsindependently258clinicianstrainedonremovals86%certifiedtodoremovalsindependentlyTrainedProvidersOutsideU.
S.
CO-84ProcedureeasilylearnedbyphysicianswithnopriorEversenseexperience99%ofremovalssuccessfulonfirstattemptLowinfectionrate(0.
5%)Europe:SuccessfulInsertionandRemovalTrainingCO-85100%ofinsertionsand99%ofremovalssuccessfulonfirstattempt91%ofinsertionsand80%ofremovalscompletedinCO-86NounanticipatedadverseeventsLimitedAEsrelatedtodeviceorprocedureAllAEsreportedresolvedfullyNoInfectionsinUSclinicaltrialsNodetectablebloodlevelsofdexamethasoneOneprocedure-relatedSAE,resolvedNodevice-relatedSAEsEversenseissafeforintendeduseEversenseSystemHasAcceptableSafetyProfileCO-87ClinicalPerspective/Benefit-RiskStevenJRussell,MD,PhDAssociateProfessorofMedicineHarvardMedicalSchoolCO-88ExperiencewithallcurrentlyapprovedCGMs(since2004)PublishedaccuracycomparisonstudiesofCGMsDevelopingbionicpancreasDependsonCGMaccuracyandreliabilityMotivatesinterestinnewCGMtechnologiesClinicalinvestigatorinartificialpancreastrialsUsedEversensesystemInsertedandremovedsensorsTrainedquicklyRelevantCGMExperienceCO-8970%notatA1ctargets*HypoglycemiastillverycommonCGMsystemsareproventohelpImproveglucosecontrolLowerriskofhypoglycemiaImprovepatients'livesCurrentSituation:MajorityofPatientsDoNotMeetGlycemicGoals*Type1DiabetesExchangeCO-90TheCurrentSituation:Only3Outof10PatientswithT1DUseCGMPerceivedburdenofrepeatinsertionFearofpainCO-91TheCurrentSituation:1outof3CGMUsersDiscontinuewithin1YearProblemswithadhesive/insertionUncomfortableCO-92Longersensorlife(90days)LessfrequentsensorinsertionsEversense:4timesperyearCurrentsystems:25–50timesperyearEasytowearandeasilyremovedForphysicalactivitiesordiscretionOn-bodyvibrationfromtransmitterprovidesextrasafetymeasureEversenseAddressesManyBarrierstoCGMUseCO-93TheGoal:IncreaseUseofCGMImproveglucosecontrolLowerriskofhypoglycemiaCO-94EversenseContinuousGlucoseMonitoring(CGM)SystemMarch29,2018Senseonics,Inc.
ClinicalChemistryandClinicalToxicologyDevicePanel
ClinicalChemistryandClinicalToxicologyDevicePanelCO-2IntroductionMukulJain,PhDChiefOperatingOfficerSenseonics,Inc.
CO-3EversenseContinuousGlucoseMonitoring(CGM)System90-dayImplantableSensorsubcutaneousRemovableTransmitterwornoverskinMobileApplicationhandhelddeviceCO-4Forcontinuallymeasuringglucoselevelsinadults(age≥18)withdiabetesforoperatinglifeofsensorSystemprovides:Real-timeglucosereadingsGlucosetrendinformationAlertsfordetectionandpredictionofepisodesoflowbloodglucose(hypoglycemia)andhighbloodglucose(hyperglycemia)Adjunctivedevicetocomplement,notreplace,informationobtainedfromstandardhomebloodglucosemonitoringdevicesProposedIndicationforUseCO-5InsertedintoupperarmLastsupto90daysMeasuresglucoseevery5minSiliconecollarcontaining1.
75mgdexamethasoneacetate(DXA)ReduceinflammationaroundsensorSystemComponents:SensorCO-6SensorTechnologyBasedonFluorescenceCO-7SystemComponents:TransmitterCalculatesglucosevaluesandtrendsWornexternallyoverinsertedsensorSecuredwithadhesivepatchVibratesforalertsandnotificationsRechargeableCO-8SystemComponents:MobileMedicalApplicationDisplaysglucoseinformationfromtransmitterValuesandtrendsAlertsandnotificationsRunsonsmartphoneRemindsusertocalibrate(2x/day)OptiontouploaddatatoSenseonics'DataManagementSystemCO-9ThresholdIdentifyglucoselevelsbeloworabovepre-setvaluesPredictiveSignalwhenalertlevelisexpectedtobecrossedinimmediatefuture(e.
g.
10minutesprior)RateofchangeIdentifyrisingorfallingglucoseexceedingpre-setrateofchangeMultipleAlertTypestoEnsureSafetyCO-10Vibratory,Visual,andAudioAlertsTransmittervibrateswhethermobileappisactiveorinvicinityUniquevibrationpatternsAudiblealertANDvisualmessageonhandhelddeviceCO-11SensorInsertedinUpperArmDuringSimple,Office-BasedProcedureSensorinserted/removedbyHCPBrief,office-basedprocedureCustominsertiontoolsProcedure:SkinanesthetizedanddisinfectedSmallincisioninupperarmBluntdissectorcreatessubcutaneouspocketSensortransferredtopocketSimilarremovalprocedureCO-12CEMarkreceivedMay2016Availablein14countries1686patientscommercially2386insertionsUpto7sequentialsensorsPMAsubmittedtoFDAinOctober2016EversenseSystemRegulatoryStatusAsofFebruary2,2018CO-13ClinicalProgram:2224PatientsFeasibilityStudiesN=332PRECISE(EU)Nov2015N=81PRECISEII(US)Jul2016N=90EuropeanPatientRegistryOngoingN=1686PRECISION(US)Feb2018N=35=OngoingstudyCO-14DesignchangessincePRECISEIITransmitterGlucosealgorithmSensorendcapBluntdissectortoolStudyresultsestablishEversenseissafeandeffectiveChangesareincrementalinnatureContinuousimprovementindesignFDADiscussionTopics:DesignChangesCO-15DesignChanges:TransmitterMoreergonomicdesignThinnerLighterLessobtrusiveWater-resistantPassedverificationandvalidationtestingExtensiveEUcommercialexperienceGeneration1PRECISEII+PRECISIONGeneration2PRECISIONCO-16GlucosealgorithmupdatedtoimproveperformanceinEarlysensorwearHypoglycemicrangeRawsensordataindependentofalgorithmintransmitterAlgorithmdevelopedwithdatafromEUpivotalstudy(PRECISE)PosthocprocessingofUSdatacollectedwithSW602EversenseperformanceaccurateandreliablewithStudySWandSW602DesignChanges:GlucoseAlgorithmSMBGCalibrationsValuesFluorescenceMeasurementsGlucoseDeterminationAlgorithmCGMValuesCO-17Amountofdatarelativetosensorlife(90days)AccuracyinearlywearperiodFDADiscussionTopics:SensorAccuracyCO-18Demonstratedaccuracy8.
5%meanabsoluterelativedifference(MARD)87%ofreadingswithin15mg/dLor15%ofreferenceExcursionsconsistentlydetected96%ofhypoglycemicexcursions*98%ofhyperglycemicexcursions*Durationofuse91%ofsensorsfunctionedfor90daysPRECISEII:EversenseSystemisHighlyAccurate*Includes70mg/dLand180mg/dLthresholdsand10-minutepredictivealertsCO-19Nodevice-relatedSAEs1procedure-relatedSAEthrough90dayspost-insertionNounanticipatedAEsLowrateofinfectionsandadhesivepatchskinreactionsAEsconsistentwithotherCGMsandsubcutaneousimplantsEversenseSystemisSafeCO-20RiskanalysisRisksareconsistent,predictable,canbemitigatedSingleinsertioncharacterizesimpact,90-dayuse,removal,andhealingClinicalstudyresultsDeviceandinsertion/removalprocedurearesafeNominal/completehealingfollowingsensorremovalPost-marketingstudiesofrepeatuseEURegistry(1686patients,upto7sequentialsensors)RepeatsensornotassociatedwithincreasedAEsRepeatSensorUseisSafeCO-21AgendaUnmetNeedJeremyH.
Pettus,MDUniversityofCaliforniaatSanDiegoStudyDesignTimGoodnow,PhDSenseonics,Inc.
EffectivenessSafetyLynneKelley,MD,FACSSenseonics,Inc.
Post-approval/TrainingClinicalPerspectiveStevenJ.
Russell,MD,PhDHarvardMedicalSchoolCO-22AdditionalExpertsClinicalPharmacologyNicholasFleischer,RPhPhDVicePresidentClinicalPharmacologyandBiopharmaceuticsTheWeinbergGroupStatisticsRichardHolcomb,PhDConsultantStudyConductKatherineTweden,PhDSenseonics,Inc.
DermatologyHowardI.
Maibach,MDDermatologistProfessorofDermatologyUniversityofCalifornia,SanFranciscoPathologyRenuVirmani,MDFACCPresidentCVPathInstituteCO-23UnmetNeedJeremyH.
Pettus,MDAssistantProfessorofMedicineEndocrinology,DiabetesandMetabolismUniversityofCalifornia,SanDiego(UCSD)CO-24CGMbenefitsImprovedoverallglucosecontrollowerHbA1clevelsIncreasedtimespentwithinnormalglucoserangeImprovedqualityoflifeCGMusesupportedbysocietyguidelines*GreatlyunderutilizedCGMOverviewPolonskyetal.
(2017)*AmericanDiabetesAssociation,EndocrineSociety,andAmericanAssociationofClinicalEndocrinologistsCO-25TARGETRANGE010020030040004812162024IntermittentMonitoringwithHomeBloodGlucoseMeterLeadstoUnnoticedHighsandLowsGlucose(mg/dL)TimeFingersticksCGM4:00AM8:00AM12:00PM4:00PM8:00PM12:00AMCO-26-0.
6-0.
5-0.
4-0.
3-0.
2-0.
100.
10.
2CO-270%20%40%60%80%100%NoCGMCGMCGMProtectsAgainstSevereHypoglycemiaPatientswithSevereHypo-glycemiaperYearA1c:7.
21A1c:7.
121.
DCCTResearchGroup(1993);2.
JDRFCGMStudyGroup(2008)1event/19months1event/60monthsCO-28CGMSystemsAreUnderutilized:76%ofPatientsDoNotUseCGMType1Diabetes(T1D)Exchangeregistry7%24%0%20%40%60%80%100%2010-20122015-2017PatientsUsingCGM(%)YearsCO-2927%ofPatientsDiscontinueCGMUseWithin1YearType1Diabetes(T1D)ExchangeRegistry(2016)ReasonN=262CGMnotworkingproperly/accurateenough71%Problemswithadhesive/insertion61%Tooexpensive/notcoveredbyinsurance58%Uncomfortabletowear41%Usingpump/don'twanttwositesonbody33%CGMtoobig28%CO-30LongersensorlifeLessfrequentsensorinsertionsCurrentsystemsrequire25–50replacements/yearEasytowearandeasilyremovedForphysicalactivitiesordiscretionAdvancementsNeededinCGMSystemsCO-31ProvenclinicalbenefitManypatientshavenotadoptedCGMtechnologyorquicklyabandonitPatientsmissingopportunitytoimprovediabetesstatusandqualityoflifeNeedmoreCGMoptionstoincreasepatientaccessNaturalEvolutionofSensorTechnology:Longer-Lasting,LessIntrusiveCO-32StudyDesignandEffectivenessTimGoodnow,PhDChiefExecutiveOfficerSenseonics,Inc.
CO-33EversenseClinicalProgramStudyDurationPatientsSitesRolePRECISEII90days908USPivotalPRECISION90days353USSupportivePRECISE180days817EUSupportiveEuropeanPatientRegistry(ongoing)2years1686350EUPost-marketFeasibilityStudiesVaried33210PilotTotal2224CO-34Non-randomized,single-arm,multi-centerstudyN=90patientsn=75onesensorinsertedn=15twosensorsinserted(oneineacharm)Sensorscalibrated2x/dayusinghomeglucosemeterGlucosereadingsandhigh/lowalertswereblindedduringstudyPRECISEII:PivotalStudyDesignCO-35PRECISEII:PivotalStudyScheduleClinicVisit1234567Day-3001306090100Screening/Follow-upAccuracy(in-clinic)Challenges**Meal,exercise,compressionchallengesInsertionAt-homewearfor90daysRemovalCO-36Meanabsoluterelativedifference(MARD)ComparessensorreadingwithreferenceglucoseSmallerMARD=higheraccuracyPercentofsensorvalueswithin15mg/dLor15%ofreferencePRECISEII:PrimaryEndpointBasedonMARDCO-37Sensoraccuracyacross90daysofuseAgreementofsensorreadingswithinaccuracylimitsHighandlowglucosealertperformanceImpactofcompressionPairedprecisionKaplan-MeieranalysisofsensorlifeMethodcomparison,biasanalysis,Clarke&ConsensusErrorAnalysisPRECISEII:AdditionalEffectivenessCharacterizationCO-38Adultsdiagnosedwithdiabetesmellitusforatleast1yearNoseverehypoglycemiawithinlast6monthsNodiabeticketoacidosisrequiringhospitalizationwithin6monthsPRECISEII:KeyEnrollmentCriteriaCO-39PRECISEIIDemographics:RepresentativeStudySampleParameterN=90SexMale60%AgeMean45yearsRaceCaucasian86%BlackorAfricanAmerican8%Asian3%Other3%BodyMassIndexMean29kg/m2GlycosylatedHemoglobin(HbA1c)Mean7.
6%TimesincediabetesdiagnosisMean20yearsDiabetestypeType168%Type232%TypeofinsulintherapyContinuousinsulininfusionpump48%Multipledailyinjections27%None(Type2,notoninsulin)22%Other(long-actinginsulinonly)3%CO-40PRECISEII:DispositionConsentedN=114CompletedSensorInsertionN=90CompletedDay1VisitN=90CompletedDay30VisitN=89CompletedDay60VisitN=86CompletedDay90VisitN=82Screenfailures(n=17)Withdrawnpriortoinsertion(n=7)Losttofollowup(n=1)Withdrawnconsent(n=2)Sensorreplacementalert(n=4)Sensorreplacementalert(n=1)CO-41PRECISEII:PrimaryEffectivenessEndpointMetUsingStudySoftwareSoftwareVersionUniquePatientsNPairedValuesNMeanAbsoluteRelativeDifference(95%CI)p-valueStudySW9015,7048.
8%(8.
3%,9.
4%)cosereadingbetweenprimarysensorandreferencevaluesCO-42PRECISEII:PrimaryEffectivenessEndpointMetUsingSW602BasedonallevaluabledatafromallpatientswithatleastonepairedglucosereadingbetweenprimarysensorandreferencevaluesSoftwareVersionUniquePatientsNPairedValuesNMeanAbsoluteRelativeDifference(95%CI)p-valueSW6029015,7538.
5%(8.
0%,9.
1%)CO-43PRECISEII:SensorAccuratethrough90DaysofUseStudyTimePointUniquePatientsNPairedValuesN%ofCGMReadingswithin15/15%ofReference(95%CI)Overall9015,75387%(84.
7%,88.
6%)Day190170877%(72.
8%,80.
4%)Day3088508191%(88.
3%,92.
6%)Day6085472587%(83.
4%,90.
4%)Day9077423985%(81.
8%,88.
4%)020406080100SW602CO-44EversenseClinicalProgramStudyDurationPatientsSitesRolePRECISEII90days908USPivotalPRECISION90days353USSupportivePRECISE180days817EUSupportiveEuropeanPatientRegistry(ongoing)2years1686350EUPost-marketFeasibilityStudiesVaried33210PilotTotal2224CO-45PRECISIONStudyDesignClinicVisit123456789Day-3001714306090100Screening/Follow-upAccuracy(in-clinic)Challenges**Mealchallenges;OvernightchallengeswereperformedonDays7and14InsertionAt-homewearfor90daysRemovalCO-463USsites35patientswithsensorsinserted27patientshad2sensorsinsertedUnblindedsensorglucosevaluesandactivehigh/lowalertsPRECISIONDifferencesfromPRECISEIICO-47PRECISION:SensorAccurateover90DaysofUseStudyTimePointUniquePatientsNPairedValuesN%ofCGMReadingswithin15/15%ofReference(95%CI)Overall3515,17085%(82.
9%,87.
5%)Day135266579%(74.
5%,83.
1%)Day735292686%(81.
5%,89.
7%)Day1435299788%(84.
7%,90.
7%)Day3035228488%(81.
3%,92.
6%)Day6035213387%(79.
7%,91.
8%)Day9035216584%(78.
4%,88.
2%)020406080100SW602CO-48AccuracyComparisonwithApprovedCGMsthroughSensorLifeDataSourcePercentofSystemReadingsWithin15/15%ofReferenceDeviceDay1Day3-4Day7Day10Day14Day30Day60Day90Eversense(SW602)PRECISEII77%91%87%85%PRECISION79%--86%--88%88%87%84%DexcomG5*--77%89%90%MedtronicGuardian(3)*--68%87%82%FreeStyleLibre*--76%82%85%85%*SummaryofSafetyandEffectivenessData(SSED)-MedicalDeviceDatabases-http://www.
fda.
govResultsbasedoncalibrationevery12hoursCO-49AlertSettingPRECISEIIDetectionRateFalseAlertRateLowGlucoseAlertat70mg/dL*96%16%HighGlucoseAlertat180mg/dL*98%7%AccurateDetectionofGlucoseExcursionsPRECISIONDetectionRateFalseAlertRate95%8%99%7%SW602*Includesthresholdand10-minutepredictivealertsCO-50PRECISEII:KMsurvivalprobabilityof91%atDay90PRECISION:Allsensorsfunctioned90daysPRECISEIIandPRECISION:EversenseSensorLongevity0.
00.
20.
40.
60.
81.
00306090SensorSurvivalProbabilityTimesinceImplant(days)0.
00.
20.
40.
60.
81.
00306090PRECISIONPRECISEIICO-51PRECISEIIandPRECISION:SystemAdherencePRECISEIIPRECISIONMedianweartime23.
4hours23.
4hours%transmittersworn>20hours/day87%91%CO-52PRECISEII:87%ofsensorreadingswith15/15%ofreferencePRECISION:85%ofsensorreadingswith15/15%ofreferenceAccurateateachmeasuredtimepointNodegradationofsensorperformance91%ofsensorsfunctionthrough90days"SensorReplacement"alertappropriatelyproducedOver95%detectionratesforglycemicexcursionsHigh(180mg/dL)andlow(70mg/dL)glucoseEffectivenessSummary:EversenseisAccuratefor90DaysCO-53ClinicalSafetyLynneKelley,MD,FACSChiefMedicalOfficerSenseonics,Inc.
CO-54EversensesystemhasacceptablesafetyprofileSimilartoothermarketedCGMsystemsProceduralrisksofimplantablesensormitigatedDevicedesign,training,andcontinuedimprovementsbasedonpost-marketsurveillanceEversensereducessomeknownrisksassociatedwithotherCGMsystemsOverviewofSafetyProfileCO-55EversenseClinicalProgramStudyDurationPatientsSitesRolePRECISEII90days908USPivotalPRECISION90days353USSupportivePRECISE180days817EUSupportiveEuropeanPatientRegistry(ongoing)2years1686350EUPost-marketFeasibilityStudiesVaried33210PilotTotal2224CO-56PRECISEIIandPRECISION:DeviceExposurePRECISEIIPRECISIONSensorsinsertedandremoved106sensors(90patients)62sensors(35patients)Proceduresperformed212procedures124proceduresSensoruse(meanduration)92.
2days91daysSensorexposure9,773days6,148daysCO-57Incidenceofdevice-relatedorinsertion/removalprocedure-relatedseriousadverseevents(SAEs)atanypointduringsensorusePRECISEIIandPRECISION:PrimarySafetyEndpointCO-58Non-seriousrelatedadverseeventsAEsofspecialintereste.
g.
infection,adhesivereactionsDexamethasoneexposureovertimePRECISEIIandPRECISION:AdditionalSafetyAnalysesCO-59PRECISEIINodevice-relatedSAEsOneprocedure-relatedSAEreportedSensorremovalsensorunsuccessful(withandwithoutultrasound)SensorsuccessfullyremovedbysurgeonundergeneralanesthesiaPRECISIONNodevice-orprocedure-relatedSAEs3unrelatedSAEsGastroenteritis,hypoglycemicepisode,cellulitisofleftfootPRECISEIIandPRECISION:SeriousAdverseEvents(SAEs)CO-60AdverseEventPRECISEIIPRECISIONEventsPatientsN=90EventsPatientsN=35AllEvents14785Pain/discomfort4222Bruising22----Erythema22----Devicefragmentnotrecovered22----Syncope11----Tingling11----Delayedreportofpain11----Secondaryproceduretoremovesensor1121Dermatitisatpatchlocation----21Skinhyperpigmentation----21PRECISEIIandPRECISION:Device-orInsertion/Removal-RelatedAEsCO-61Allremovedsensorsreturnedtosponsorforinspection2devicesdidnothavecapuponreturnCorrectiveandpreventativeactionplanimplementedImplementingenhancedqualityprocedures(capadhesion)Capmaterial:PMMAhighlybiocompatible,permanentimplantOrthopedic,dental,andophthalmologicCapsize:3.
2mmx0.
8mmPRECISEII:TwoEventsRelatedtoDeviceFragmentCO-62NoinfectionsAllrelatedAEsconsideredexpectedandcommonforsubcutaneousimplantAllrelatedAEsresolvedfullyPRECISEIIandPRECISION:AdditionalSafetyOutcomesCO-63Contains1.
75mgdexamethasoneacetate(DXA)Water-insolublecorticosteroidReduceslocalinflammatoryresponseExtendssensorlifeControlledandslowDXAreleaseconeCollarCO-64BloodassayedforDXAto50pg/mLlevelNodetectableplasmalevelsofDXAobservedNosystemiceffectsDXAcollarsexaminedafterremovalMinimalDXAexposureconfirmed3μg/day2eventsoftransienthyperpigmentationResolveduponsensorremovalImpactofDexamethasoneExposureCO-65EversenseClinicalProgramStudyDurationPatientsSitesRolePRECISEII90days908USPivotalPRECISION90days353USSupportivePRECISE180days817EUSupportiveEuropeanPatientRegistry(ongoing)2years1686350EUPost-marketFeasibilityStudiesVaried33210PilotTotal2224CO-66Threemulti-centerstudiesPRECISEII,PRECISION,andPRECISE206subjects335sensors670insertion/removalprocedures22,529patient-daysofsensorwearIntegratedDeviceExposureCO-67IntegratedSummaryofRelatedAdverseEventsAdverseEventEventsPatientsN=206AllEvents4126(13%)Pain/discomfort108(4%)Redness/erythema66(3%)Secondaryproceduretoremovesensor43(1%)Infection33(1%)Bruising/hematoma33(1%)Devicefragmentnotrecovered22(1%)Dermatitisatpatchlocation32(1%)Skinhyperpigmentation21(cope,hypertension,andnauseaCO-68Aggregateinfectionrate1%ImprovedincisioncareinstructionsPRECISE:leavebandagefor24hoursPRECISEII:leavebandagefor48hoursInfectionrateobservedisbelowliteraturereportsforsimilarimplantsandminorprocedures:2–4%*LowRateofInfectionsObservedinStudies*Buprenorphine,BraeburnPharmaceuticals,Inc.
*http://www.
worldwidewounds.
com/2005/september/Gottrup/Surgical-Site-Infections-Overview.
htmlCO-69EversenseClinicalProgramStudyDurationPatientsSitesRolePRECISEII90days908USPivotalPRECISION90days353USSupportivePRECISE180days817EUSupportiveEuropeanPatientRegistry(ongoing)2years1686350EUPost-marketFeasibilityStudiesVaried33210PilotTotal2224CO-70AllpatientsinsertedcommerciallyenrolledinregistryEnrollmentcompletedwhen100patientsreach4insertionsAllpatientsenrolledtobefollowedthrough8insertionsandremovalsEuropeanPatientRegistryCO-71LowRateofAEswithRepeatInsertionsEvents,n(%)PostInsertion#1N=16862N=4433N=1434N=585N=396N=147N=3SAEs0000000Device-,procedure-relatedAEsInfection(atsensorsite)8(0.
5%)4(1%)2(1%Secondaryproceduretoremovesensor72Adhesivepatchsiteirritation5-2----Prolongedwoundhealing3Redness/reactiontodressing3Sensorbrokeduringremoval3Skinatrophyoversensorw/skindiscoloration21Skinatrophyoversensor1Skindiscoloration12Sensorsitepain/discomfort1Bruising11-1---Patientfaintedduringprocedure1Hematoma---1---CO-72ProposedPost-ApprovalStudyCO-73Serialsensorinsertionsandremovalsfor2years175patientsinupto20clinicalsitesPrimarysafetyendpointRateofdevice-relatedandinsertion/removalprocedure-relatedSAEsthrough12months≤7%PrimaryeffectivenessendpointTimeinrange(between70mg/dLand180mg/dL),12monthsvs.
firstmonthProposedU.
S.
PostApprovalStudyDesignCO-74AllrelatedAEsthrough2yearsPlasmadexamethasonelevelsevery6monthsEffectivenessoftrainingprogramSuccessrateofinsertions/removalsDiabetesdistressscaleandCGMsatisfactionscaleBaselineandannuallyProposedU.
S.
PostApprovalStudy:OtherOutcomeMeasuresCO-75DesignChangesSensorendcapBluntdissectortoolCO-76SensorEndCapImprovementOriginalDesignNewDesignEndcapredesignedtobeflushwithendofsensorDesignverificationCompressiveforcesTorqueMaintainsfunctionalcompatibilitywithinsertiontoolCO-77BluntDissectorDesignImprovementSamefunctionConsistentplacementfacilitatesremovalProperentryanglePocketdepth/lengthParalleltoskinValidatedwithHumanFactorstestingNewBluntDissectorOriginalBluntDissectorNewguidesCO-78TrainingforCliniciansCO-79MandatorycomprehensivetrainingCertificationprocessledbySenseonicsapprovedtrainersDidacticsessionPracticeswithsimulatedskinInitialinsertionsandremovalsareobservedTrainingProgramOverviewTrainingresources:CGMSensorInsertionandRemovalInstructionsInsertionvideosRemovalvideosSimulationstationProcedureposterTake-homeinstructionsCO-80TrainingChecklistforCertificationPre-WorkbeforeSimulationTrainingInsertionSimulationTrainingPre-WorkbeforeRemovalReviewRemovalSimulationTrainingLearningcurve:~2to3procedures3patientsscheduledinsamedaytofamiliarizewithprocedureCO-81Hands-OnPracticeSessionwithSimulatedSkin,SterileField,andRequiredSuppliesCO-82ExamplesofTrainingMaterialsCO-83461clinicianstrainedoninsertions94%certifiedtodoinsertionsindependently258clinicianstrainedonremovals86%certifiedtodoremovalsindependentlyTrainedProvidersOutsideU.
S.
CO-84ProcedureeasilylearnedbyphysicianswithnopriorEversenseexperience99%ofremovalssuccessfulonfirstattemptLowinfectionrate(0.
5%)Europe:SuccessfulInsertionandRemovalTrainingCO-85100%ofinsertionsand99%ofremovalssuccessfulonfirstattempt91%ofinsertionsand80%ofremovalscompletedinCO-86NounanticipatedadverseeventsLimitedAEsrelatedtodeviceorprocedureAllAEsreportedresolvedfullyNoInfectionsinUSclinicaltrialsNodetectablebloodlevelsofdexamethasoneOneprocedure-relatedSAE,resolvedNodevice-relatedSAEsEversenseissafeforintendeduseEversenseSystemHasAcceptableSafetyProfileCO-87ClinicalPerspective/Benefit-RiskStevenJRussell,MD,PhDAssociateProfessorofMedicineHarvardMedicalSchoolCO-88ExperiencewithallcurrentlyapprovedCGMs(since2004)PublishedaccuracycomparisonstudiesofCGMsDevelopingbionicpancreasDependsonCGMaccuracyandreliabilityMotivatesinterestinnewCGMtechnologiesClinicalinvestigatorinartificialpancreastrialsUsedEversensesystemInsertedandremovedsensorsTrainedquicklyRelevantCGMExperienceCO-8970%notatA1ctargets*HypoglycemiastillverycommonCGMsystemsareproventohelpImproveglucosecontrolLowerriskofhypoglycemiaImprovepatients'livesCurrentSituation:MajorityofPatientsDoNotMeetGlycemicGoals*Type1DiabetesExchangeCO-90TheCurrentSituation:Only3Outof10PatientswithT1DUseCGMPerceivedburdenofrepeatinsertionFearofpainCO-91TheCurrentSituation:1outof3CGMUsersDiscontinuewithin1YearProblemswithadhesive/insertionUncomfortableCO-92Longersensorlife(90days)LessfrequentsensorinsertionsEversense:4timesperyearCurrentsystems:25–50timesperyearEasytowearandeasilyremovedForphysicalactivitiesordiscretionOn-bodyvibrationfromtransmitterprovidesextrasafetymeasureEversenseAddressesManyBarrierstoCGMUseCO-93TheGoal:IncreaseUseofCGMImproveglucosecontrolLowerriskofhypoglycemiaCO-94EversenseContinuousGlucoseMonitoring(CGM)SystemMarch29,2018Senseonics,Inc.
ClinicalChemistryandClinicalToxicologyDevicePanel
Virmach（$5.23/年）年付VPS闪购
每每进入第四季度，我们就可以看到各大云服务商的促销力度是一年中最大的。一来是年底的促销节日活动比较多，二来是商家希望最后一个季度冲刺业绩。这不还没有到第四季度，我们看到有些商家已经蠢蠢欲动的开始筹备活动。比如素有低价VPS收割机之称的Virmach商家居然还没有到黑色星期五就有发布黑五促销活动。Virmach 商家有十多个数据中心，价格是便宜的，但是机器稳定性和速度肯定我们也是有数的，要不这么低的...
hostkvm：美国VPS，三网强制CU-VIP线路，$5/月，1G内存/1核/15gSSD/500g流量
hostkvm在2021年3月新上线洛杉矶新VPS业务，强制三网接入中国联通优化线路，是当前中美之间性价比最高、最火热的线路之一，性价比高、速度非常好，接近联通AS9929和电信AS4809的效果，带宽充裕，晚高峰也不爆炸。 官方网站：https://hostkvm.com 全场优惠码：2021（全场通用八折，终身码，长期） 美国 US-Plan0【三网联通优化线路】 内存：1G CPU：...
Advinservers：美国达拉斯便宜VPS/1核/4GB/80GB SSD/1Gbps不限流量/月付$2.5/美国10Gbps高防服务器/高达3.5TBDDos保护$149.99元/月
Advinservers，国外商家，公司位于新泽西州，似乎刚刚新成立不久，主要提供美国和欧洲地区VPS和独立服务器业务等。现在有几款产品优惠，高达7.5TB的存储VPS和高达3.5TBDDoS保护的美国纽约高防服务器，性价比非常不错，有兴趣的可以关注一下，并且支持Paypal付款。官方网站点击直达官方网站促销产品第一款VPS为预购，预计8月1日交付。CPU为英特尔至强 CPU（X 或 E5）。官方...
co为你推荐
-
网页解密急急急～～谁知道怎么让所有的网页都设密码？以及破解的办法啊？ 谢谢了谁帮帮我啊iphone5解锁苹果5手机怎么屏幕解锁深圳公交车路线深圳公交线路网站运营刚创业的网站运营怎么做？腾讯文章为什么最近腾讯网的文章评论都看不到硬盘人移动硬盘的优缺点qq怎么发邮件qq怎么发文件和邮件lockdownd[求教]在淘宝买了张激活卡，请问怎么取消激活mate8价格现在买华为mate8高配划算吗机械键盘轴机械键盘蓝轴有什么作用